Screener
Aquestive Therapeutics, Inc. AQST Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:08 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000030
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Research and development | 4,204 | 5,361 |
| Selling, general and administrative | 10,977 | 19,072 |
| Total costs and expenses | 18,650 | 28,085 |
| Loss from operations | (4,204) | (19,365) |
| Other income/(expenses): | ||
| Interest expense | (2,903) | (2,782) |
| Interest expense related to royalty obligations | (973) | (1,437) |
| Interest expense related to the sale of future revenue | (60) | (59) |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s operating income?
- Aquestive Therapeutics, Inc. (AQST) reported operating income of -$4.2M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s operating income changed year-over-year?
- Aquestive Therapeutics, Inc.'s operating income increased by 78.3% year-over-year, from -$19.37M to -$4.2M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s operating income?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s operating income has grown at a 19.6% compound annual growth rate (CAGR), from -$34.68M to -$71.05M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Aquestive Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude